Basis: Latest reported fiscal quarter. Source: stored company filings and market data; unavailable inputs remain N/A.
The earnings per share (EPS) is N/A as of the fiscal period ended Wednesday, December 31, 2025.
Reported quarterly EPS; no daily interpolation. Q2 FY2026 (2026-06-30): -0.91.
EPS growth vs the same fiscal quarter in the prior fiscal year, last 13 comparable quarters.
EARNINGS PER SHARE (EPS)
N/A
EARNINGS PER SHARE (EPS) AVG TTM
-60.73
EARNINGS PER SHARE (EPS) AVG 3Y
-46926.80
EARNINGS PER SHARE (EPS) AVG 5Y
-32538.00
EARNINGS PER SHARE (EPS) AVG 10Y
N/A
EARNINGS PER SHARE (EPS) AVG 15Y
N/A
EARNINGS PER SHARE (EPS) AVG 20Y
N/A
CURRENT VS TTM AVG
N/A
CURRENT VS 3Y AVG
N/A
CURRENT VS 5Y AVG
N/A
CURRENT VS 10Y AVG
N/A
CURRENT VS 15Y AVG
N/A
CURRENT VS 20Y AVG
N/A
GRI Bio, Inc.
Market Cap
$4.20M
Earnings Per Share (EPS)
N/A
TTM Avg
-60.73
3Y Avg
-46926.80
5Y Avg
-32538.00
Market Cap
$4.26M
Earnings Per Share (EPS)
-0.76
TTM Avg
-0.88
3Y Avg
-0.66
5Y Avg
-0.44
Market Cap
$4.10M
Earnings Per Share (EPS)
-5.60
TTM Avg
-53.55
3Y Avg
-292.57
5Y Avg
-468.76
Market Cap
$4.05M
Earnings Per Share (EPS)
-211.18
TTM Avg
-432751.00
3Y Avg
-875189.50
5Y Avg
-22462429.83
Market Cap
$4.00M
Earnings Per Share (EPS)
-18.85
TTM Avg
-47.63
3Y Avg
-99.69
5Y Avg
-316.96
Market Cap
$4.43M
Earnings Per Share (EPS)
-9.39
TTM Avg
-11.95
3Y Avg
-11.32
5Y Avg
-8.88
Market Cap
$4.45M
Earnings Per Share (EPS)
-2.41
TTM Avg
0.21
3Y Avg
-0.40
5Y Avg
-0.72
Market Cap
$4.50M
Earnings Per Share (EPS)
-4.39
TTM Avg
-44.24
3Y Avg
-644.57
5Y Avg
-610.60
Market Cap
$4.69M
Earnings Per Share (EPS)
-3.64
TTM Avg
-254.03
3Y Avg
-3442.01
5Y Avg
-5629.67
| NAME | MARKET CAP | EARNINGS PER SHARE (EPS) | TTM | 3Y | 5Y |
|---|---|---|---|---|---|
| GRI Bio, Inc. (GRI) | $4.20M | N/A | -60.73 | -46926.80 | -32538.00 |
| 20/20 Biolabs Inc. (AIDX)vs › | $4.26M | -0.76 | -0.88 | -0.66 | -0.44 |
| Processa Pharmaceuticals, Inc. (PCSA)vs › | $4.10M | -5.60 | -53.55 | -292.57 | -468.76 |
| Aptevo Therapeutics Inc. (APVO)vs › | $4.05M | -211.18 | -432751.00 | -875189.50 | -22462429.83 |
| Ernexa Therapeutics Inc. (ERNA)vs › | $4.00M | -18.85 | -47.63 | -99.69 | -316.96 |
| CollPlant Biotechnologies Ltd. (CLGN)vs › | $4.43M | -9.39 | -11.95 | -11.32 | -8.88 |
| PharmaCyte Biotech, Inc. (PMCB)vs › | $4.45M | -2.41 | 0.21 | -0.40 | -0.72 |
| Dermata Therapeutics, Inc. (DRMA)vs › | $4.50M | -4.39 | -44.24 | -644.57 | -610.60 |
| Bio Green Med Solution, Inc. (BGMS)vs › | $4.69M | -3.64 | -254.03 | -3442.01 | -5629.67 |
| Lexaria Bioscience Corp. (LEXX)vs › | $4.77M | -5.32 | -8.47 | -12.67 | -14.30 |
Trailing EPS (TTM)
N/A
Forward EPS (Est.)
$-3.89
P/E Ratio
N/A
Formula: EPS = Net Income / Weighted Average Shares Outstanding
Why EPS matters:
EPS (Earnings Per Share) represents the portion of a company's profit allocated to each outstanding share. Higher EPS indicates greater profitability on a per-share basis.
Expanded definitions: Investopedia, Wikipedia, Corporate Finance Institute
| DATE | EARNINGS PER SHARE (EPS) |
|---|---|
| 2025-12-31 | -121.80 |
| 2024-12-31 | 0.33 |
| 2023-12-31 | -140450.24 |
| 2022-12-31 | -47135.48 |
| 2021-12-31 | -2827.16 |
| 2020-12-31 | -4693.64 |
| 2019-12-31 | -660968.00 |
| 2018-12-31 | -822780.00 |
